On Monday, Bank of America (NYSE:BAC) (BofA) increased its price target on AbbVie (NYSE:ABBV) to $167 from $165, while maintaining... ByInvesting.com • Feb 05, 2024 Goldman Sachs raises AbbVie stock ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

So, you want to invest in AbbVie (ABBV 1.21%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure.

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Wells Fargo on March 5, 2025. The analyst firm set a price target for $240.00 expecting ABBV to rise to within 12 months (a possible ...

Our reporting shows this will be painful for many biopharma companies who rely on funds from the sale of PRVs. Speaking of money, AbbVie and Eli Lilly struck a pair of mid-size deals in hot spaces.

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

AbbVie Inc. agreed to pay as much as $2.2 billion for a next-generation obesity drug from Danish biotech Gubra A/S, marking its entry into the hyper-competitive weight-loss market. The licensing deal ...

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug ...